Advertisement
Singapore markets close in 2 hours 21 minutes

  • Straits Times Index

    3,279.92
    -13.21 (-0.40%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,233.43
    +32.16 (+0.19%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Bitcoin USD

    64,339.21
    -2,351.18 (-3.53%)
     

  • CMC Crypto 200

    1,390.94
    +8.37 (+0.61%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,331.70
    -6.70 (-0.29%)
     

  • Crude Oil

    82.95
    +0.14 (+0.17%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,570.29
    -1.19 (-0.08%)
     

  • Jakarta Composite Index

    7,157.23
    -17.30 (-0.24%)
     

  • PSE Index

    6,585.40
    +12.65 (+0.19%)
     

Will Demand for Rapid COVID-19 Tests Help Abbott Laboratories Beat the Market in 2022?

Alex Carchidi, The Motley Fool
·4-min read
Will Demand for Rapid COVID-19 Tests Help Abbott Laboratories Beat the Market in 2022?

In particular, Abbott Laboratories (NYSE: ABT) makes BinaxNOW kits, which are the most popular rapid coronavirus antigen diagnostic test in the U.S. Are things different this time as a result of the omicron variant wave, or is Abbott on track to disappoint? Coronavirus rapid testing revenue has been all over the place, appearing to ebb and flow based on the public's perceptions about where the pandemic is headed.

Continue reading